Oncodesign Precision Medicine (OPM), a biopharmaceutical company, engages in the precision medicine business. It offers diagnostic and therapeutic solutions for resistant and metastatic cancers. The company is based in Dijon, France. As of October 19, 2022, Oncodesign Precision Medicine Société anonyme operates as a subsidiary of Edmond de Rothschild Equity Strategies Management III S.à.r.l.
Stock data | 2024 | Change |
---|---|---|
Price | $1.05 | N/A |
Market Cap | $17.42M | N/A |
Shares Outstanding | 16.59M | N/A |
Employees | 0 | N/A |